(2) Possible prognostic biomarkers including PTEN deletion, PIK3CA mutations, p70S6K and 4E-BP1 for tumor response to mTOR inhibitors have been illustrated in glioblastoma, breast and prostate cancer cells cultured in vitro [30, 31], whether these biomarkers may contribute to the prognosis and individual therapy of EA in clinic? This evidence concerns the gene MTOR and neoplasm.